{"id":"W4288034414","doi":"10.1093/oncolo/oyac142","title":"Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Merck Sharp and Dohme; Eisai; Merck","keywords":"Lenvatinib; Medicine; Everolimus; Renal cell carcinoma; Quality of life (healthcare); Internal medicine; Oncology; Adverse effect; Clinical trial; Sorafenib; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001774872,0.0005513503,0.001443842,0.0003592488,0.0002881877,0.0005412813,0.0004619503,0.0004385457,0.001652385],"category_scores_gemma":[0.002080109,0.0002073,0.001509283,0.0004057596,0.000307624,0.000366293,0.000285408,0.001321861,0.0002484996],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008242261,"about_ca_system_score_gemma":0.0007307606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005284855,"about_ca_topic_score_gemma":0.001124934,"domain_scores_codex":[0.999024,0.0004372988,0.00008734482,0.0001519202,0.0002062954,0.00009319352],"domain_scores_gemma":[0.9984385,0.0003957564,0.0006600411,0.00009233023,0.000113871,0.0002995168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6173586,0.02504114,0.2086514,0.0004644936,0.004990028,0.0001786816,0.0002805075,0.004509712,0.0220394,0.0000656189,0.001023369,0.1153971],"study_design_scores_gemma":[0.06652014,0.3502476,0.5657918,0.000060452,0.002347079,0.0003977189,0.00008670819,0.003480823,0.01001788,0.0001667479,0.0008247323,0.00005827217],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9988664,0.000500663,0.00008190452,0.00003581448,0.000009570053,0.00008352599,0.0001964493,0.000006780084,0.0002188307],"genre_scores_gemma":[0.998716,0.0001628596,0.000294938,0.00004671655,0.00002228797,0.0001932881,0.0004466629,0.000003284546,0.0001140616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001774872,"threshold_uncertainty_score":0.009386539,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06752936432084708,"score_gpt":0.3277357303072121,"score_spread":0.260206365986365,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}